These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 12755606)

  • 21. Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase.
    DeMartino JK; Hwang I; Connelly S; Wilson IA; Boger DL
    J Med Chem; 2008 Sep; 51(17):5441-8. PubMed ID: 18686942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human glycinamide ribonucleotide transformylase: active site mutants as mechanistic probes.
    Manieri W; Moore ME; Soellner MB; Tsang P; Caperelli CA
    Biochemistry; 2007 Jan; 46(1):156-63. PubMed ID: 17198385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of a potent, nonpolyglutamatable inhibitor of glycinamide ribonucleotide transformylase.
    DeMartino JK; Hwang I; Xu L; Wilson IA; Boger DL
    J Med Chem; 2006 May; 49(10):2998-3002. PubMed ID: 16686541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crystal structure and mechanism of the Escherichia coli ArnA (PmrI) transformylase domain. An enzyme for lipid A modification with 4-amino-4-deoxy-L-arabinose and polymyxin resistance.
    Gatzeva-Topalova PZ; May AP; Sousa MC
    Biochemistry; 2005 Apr; 44(14):5328-38. PubMed ID: 15807526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, and biological evaluation of 10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF, and 10-methylthio-DDACTHF as potent inhibitors of GAR Tfase and the de novo purine biosynthetic pathway.
    Cheng H; Chong Y; Hwang I; Tavassoli A; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
    Bioorg Med Chem; 2005 May; 13(10):3577-85. PubMed ID: 15848770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 10-Formyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid (10-formyl-DDACTHF): a potent cytotoxic agent acting by selective inhibition of human GAR Tfase and the de novo purine biosynthetic pathway.
    Marsilje TH; Labroli MA; Hedrick MP; Jin Q; Desharnais J; Baker SJ; Gooljarsingh LT; Ramcharan J; Tavassoli A; Zhang Y; Wilson IA; Beardsley GP; Benkovic SJ; Boger DL
    Bioorg Med Chem; 2002 Aug; 10(8):2739-49. PubMed ID: 12057663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Towards structure-based drug design: crystal structure of a multisubstrate adduct complex of glycinamide ribonucleotide transformylase at 1.96 A resolution.
    Klein C; Chen P; Arevalo JH; Stura EA; Marolewski A; Warren MS; Benkovic SJ; Wilson IA
    J Mol Biol; 1995 May; 249(1):153-75. PubMed ID: 7776369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 10-(2-benzoxazolcarbonyl)-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid: a potential inhibitor of GAR transformylase and AICAR transformylase.
    Marsilje TH; Hedrick MP; Desharnais J; Capps K; Tavassoli A; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
    Bioorg Med Chem; 2003 Oct; 11(20):4503-9. PubMed ID: 13129586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological evaluation of alpha- and gamma-carboxamide derivatives of 10-CF3CO-DDACTHF.
    Chong Y; Hwang I; Tavassoli A; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
    Bioorg Med Chem; 2005 May; 13(10):3587-92. PubMed ID: 15848771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid.
    Zhang Y; Desharnais J; Marsilje TH; Li C; Hedrick MP; Gooljarsingh LT; Tavassoli A; Benkovic SJ; Olson AJ; Boger DL; Wilson IA
    Biochemistry; 2003 May; 42(20):6043-56. PubMed ID: 12755606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
    Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contributions of protein structure-based drug design to cancer chemotherapy.
    Jackson RC
    Semin Oncol; 1997 Apr; 24(2):164-72. PubMed ID: 9129687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
    Lu H; Tonge PJ
    Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.